All In Biotech

Drug Trial Radar · NCT04467983

Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Feb 1, 2021

Primary completion

Sep 18, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Hospital for Special Surgery, New YorkAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Radius Health, Inc.; Crozer-Keystone Health System
First posted
Jul 13, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This randomized open label clinical trial will evaluate the effect of continued denosumab alone over 18 months versus denosumab with added abaloparatide for 18 months. 70 postmenopausal women will be enrolled over a period of 18 months. The co-primary outcomes will be group differences in bone mineral density (BMD) of the total hip and lumbar spine at 18 months. Secondary outcomes will include group differences in bone mineral density (BMD) at the femoral neck, trochanter and wrist sites at 6, 12 and 18 months, spine and total hip bone mineral density (BMD) at 6 and 12 months and trabecular bone score (TBS) at 18 months. Secondary outcomes will also include within group changes from baseline for each of these variables. Bone turnover markers will also be measured to demonstrate that PINP levels will increase with administration of abaloparatide even in the setting of ongoing denosumab, while CTX levels will remain low.

Conditions

  • Osteoporosis, Postmenopausal

Interventions

  • Denosumab InjectionDrug

    Denosumab alone: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment.

  • AbaloparatideDrug

    Combination therapy: 3 injections of Denosumab at appropriate times, separated by no more than 7 months from the last treatment, with added abaloparatide 80 mcg subcutaneously daily, started within 6 months of the last denosumab treatment, for a total of 18 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bone mineral density changes at total hip and lumbar spineTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital for Special Surgery

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.